top of page
.png)
Eyes on Pharma
Check-out What Intel Caught our Eye
Eyes On MASH, IPF, and the MFN pricing program
We've had Eyes on the MASH activities, and the latest M&A between Novo Nordisk and Akero Therapeutics caught our eye. In IPF, Boehringer's newly approved Jascayde...
Jana Chisholm
Oct 2710 min read
Eyes On Clinical Data & FDA News: Huntington's, Psoriasis, PTSD, MASH, and Autism
Lately we've had Eyes On: Clinical Data, FDA news, M&A, and more. Read more about uniQure's AMT-130 data for Huntington's Disease, Roche's acquisition of 89bio for MASH, JnJ's Iconic Advance Data for Psoriasis, Lundbeck's CRL letter for PTSD, and the latest buzz around acetaminophen.
Jana Chisholm
Oct 1911 min read
bottom of page